Biochemical markers of bone turnover, serum levels of interleukin-6/interleukin-6 soluble receptor and bisphosphonate treatment in Erdheim-Chester disease

Clinical and Experimental Rheumatology

Volumn 21, Issue 2, 2003, Pages 232-236

  Mossetti, Giuseppe ^a   Rendina, Domenico ^a   Numis, Fabio G ^a   Somma, Pasquale ^a   Postiglione, Loredana ^a   Nunziata, Vicenzo ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

Bone turnover; Erdheim Chester disease; Interleukin 6; Interleukin 6 soluble receptor; Non Langherans histiocytosis

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BIOCHEMICAL MARKER; BISPHOSPHONIC ACID DERIVATIVE; CLODRONIC ACID; ERGOTAMINE; INTERLEUKIN 6; INTERLEUKIN 6 RECEPTOR; METHYSERGIDE; PREDNISONE; STEROID;

ADULT; ARTICLE; BLOOD LEVEL; BONE RADIOGRAPHY; BONE TURNOVER; CASE REPORT; CLINICAL FEATURE; CYTOKINE PRODUCTION; DIAPHYSIS; DISEASE COURSE; ERDHEIM CHESTER DISEASE; HISTIOCYTOSIS; HUMAN; HUMAN CELL; HUMAN TISSUE; LONG BONE; MACROPHAGE; MALE; METAPHYSIS; OSTEOLYSIS; OSTEOSCLEROSIS; PATHOLOGY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; TIME;

ANTI-INFLAMMATORY AGENTS; ANTIMETABOLITES; BIOLOGICAL MARKERS; BONE REMODELING; CLODRONIC ACID; DIPHOSPHONATES; ERDHEIM-CHESTER DISEASE; HUMANS; INTERLEUKIN-6; MALE; MIDDLE AGED; PREDNISONE; RECEPTORS, INTERLEUKIN-6; TREATMENT OUTCOME;

EID: 0037367862     PISSN: 0392856X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. VEYSSIER-BELOT C, CACOUB P, CAPARROS-LEFEBVRE D et al.: Erdheim-Chester disease. Clinical and radiologic characteristics of 59 cases. Medicine (Baltimore) 1996; 75: 157-69.
2. MILLER RL, SHEELER LR, BAUER TW, BUKOWSKI RM: Erdheim-Chester disease. Case report and review of the literature. Am J Med 1986; 80: 1230-6.
3. CHETRITT J, PARADIS V, DARGERE D et al.: Chester-Erdheim disease: A neoplastic disorder. Hum Pathol 1999; 30: 1093-6.
4. Al-QURAN S, REITH J, BRADLEY J, RIMSZA L: Erdheim-Chester disease: case report, PCR-based analysis of clonality, and review of literature. Mod Pathol 2002; 15: 666-72.
5. AKIRA S, KISHIMOTO T: Role of interleukin 6 in macrophage function. Curr Op Haematol 1996; 3: 87-93.
6. JONES SA, HORIUCHI S, TOPLEY N, YAMAMOTO N, FULLER GM: The soluble interleukin 6 receptor: mechanism of production and implication in disease. FASEB J 2001; 15: 43-58.
7. GOTTHARDT M, WELCKE U, BRANDT D et al.: The role of bone scintigraphy in patients with Erdheim-Chester disease. Clin Nucl Med 2000; 25: 414-20.
8. DELMAS PD, MEUNIER PJ: The management of Paget's disease of bone. N Engl J Med 1997; 336: 558-66.
9. RUSSEL RGG, ROGERS MJ, FRITH JC et al.: The pharmacology of bisphosphonates and new insights into their mechanism of action. J Bone Miner Res 1999; 14: 53-65.
10. ROODMAN GD, KURIHARA N, OHSAKI Y: Interleukin 6: A potential autocrine/paracrine factor in Paget's disease of bone. J Clin Invest 1992; 89: 46-52.
11. 2 and calcemic hormones of IL-6 in stromal/osteoblastic cells. Biochem Biophys Res Commun 2000; 270: 1080-5
12. AMMANN P, BOSCH B, BUCHHOLZ S, GENONI M, LAUBE I, NAEGELI B: Cardiac tumor due to Erdheim-Chester disease. Am J Med 2001; 111: 672-3.
13. EGELER RM: More on pamidronate in Langerhan's cell histiocytosis. N Engl J Med 2001; 345: 1502-3
14. BROWN RE: Bisphosphonates as antialveolar macrophage therapy in pulmonary Langerhans cell histiocytosis ? Med Pediatr Oncol 2001; 36: 641-3.
15. RENDINA D, POSTIGLIONE L, VUOTTO P et al.: Clodronate treatment reduces serum levels of interleukin-6 soluble receptor in Paget's disease of bone. Clin Exp Rheumatol 2002; 20: 359-64.